No products in the cart.
CBD and THC: the compounds changing cannabis medicine
3 minute read · Drakensberg Cannabis Journal
A plant once discussed mainly through its intoxicating effects is helping researchers rethink seizures, nausea and pain. CBD and THC sit at the heart of that change.
There is a reason cannabis science has become so compelling. Behind the familiar leaf are compounds capable of producing measurable changes in the human body. Some of those effects have moved beyond an intriguing laboratory observation into controlled clinical trials and established medicines.
For people who have spent years searching for relief, that shift matters. It gives a more substantial answer to the question, “Could a plant-derived treatment have something useful to offer me?” The answer increasingly depends on the condition and the compound, rather than on a simple judgement about cannabis as a whole.
Two compounds, different possibilities
THC—delta-9-tetrahydrocannabinol—is the main intoxicating cannabinoid in cannabis. CBD, or cannabidiol, does not produce the same high. Both are biologically active, and their differences help explain why a CBD study and a THC-containing treatment can tell quite different stories. The CDC’s CBD overview provides the basic distinction.
| Compound | A clinical research landmark | What was actually studied |
|---|---|---|
| CBD | Reduced convulsive seizures in Dravet syndrome. | A purified oral medicine added to existing treatment. |
| THC + CBD | Better control of chemotherapy-related nausea and vomiting. | A defined oral combination added to standard anti-nausea care. |
The seizure trial that changed the conversation
In a landmark 2017 trial, 120 children and young adults with treatment-resistant Dravet syndrome received a purified CBD medicine or placebo alongside their existing care. Median convulsive-seizure frequency fell by 38.9% with CBD, compared with 13.3% with placebo. For a severe epilepsy that had resisted other approaches, this was a significant clinical advance. Diarrhoea, sleepiness and other adverse effects were more common with CBD. Read the trial in the New England Journal of Medicine.
The importance of this work reaches beyond one headline. It established that a cannabis-derived molecule could be investigated with the same rigour as any other treatment and deliver a meaningful result. It also showed why medical formulations, monitoring and the intended condition belong in the story.
One of cannabis research’s most important achievements is making a once-dismissed possibility into a question medicine can test.
A second opening: relief during chemotherapy
In a 2024 phase II/III trial involving 147 evaluable adults, oral THC:CBD was added when standard anti-nausea medicines had not controlled chemotherapy-related symptoms. A complete response—no vomiting or retching and no rescue medication during the measured period—occurred in 24% of the cannabis group versus 8% with placebo. Sedation, dizziness and transient anxiety occurred more often with THC:CBD. The published trial supports an additional option for difficult symptoms, not a replacement for cancer treatment.
That distinction is practical. Relief can mean being able to eat, rest or approach the next treatment cycle with less dread. Supportive care deserves serious attention because the experience of living through treatment matters as well as the treatment itself.
Where does full-spectrum fit?
“Full-spectrum” describes a preparation containing a wider range of cannabis constituents. It does not specify a single recipe. The relative amounts of THC, CBD and other compounds can vary, so a useful description includes the measured cannabinoid profile and the intended route of use. A CBD-rich oil and a THC-dominant extract may both come from cannabis while offering very different experiences.
These trials concern defined medical preparations; they are not clinical tests of our club’s oils or balms. They do, however, explain why we take the plant seriously. Its potential is substantial enough to deserve curiosity, careful cultivation and precise discussion.
For anyone considering a change to prescribed treatment, the next step is a treatment-specific conversation with a clinician. The exciting prospect is having more well-understood choices—and better ways to match those choices to the person.
Research & further reading
- Devinsky et al., 2017: CBD in Dravet syndrome
- Grimison et al., 2024: THC:CBD for chemotherapy-related nausea
- CDC: CBD and THC background
Research reviewed 26 October 2026.
Featured photograph: Jeff W / Unsplash. Illustrative stock photography; not a record of our premises or production.